Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug Candidate, Sphingomab
Sphingomab Shows Near-Complete Mitigation of Choroidal Neovascularization (CNV) in an AMD Model SAN DIEGO, May 22, 2007 /PRNewswire-FirstCall/ -- Lpath, Inc. , the category leader in therapeutic agents against bioactive lipids, reported compelling proof-of-concept data in a standard animal model o...Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
...ing with them again on our Lpathomab project." This achievement with Lpathomab comes on the heels of Lpath's success with its Sphingomab(TM) program. sphingomab is an antibody against another bioactive lipid, S1P. Lpath humanized the antibody in 2006 and plans to file an IND in November of this year for the us...About - Business & Finance - MEDIAVIEWER
Sphingomab is potently anti-angiogenic, yet it has other ... As such, Lpath believes Sphingomab may represent the next ... Sphingomab is a trademark ...PipelineReview.com - Biotech News & Online Store - Lpath Humanizes Its ...
... Biopharmaceutical Industry, Lpath Humanizes Its Anti-S1P Antibody Sphingomab(TM) ... murine (mouse-based) form of Sphingomab was the first antibody created ...PipelineReview.com - Biotech News & Online Store - Lpath Demonstrates ...
... Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM... Sphingomab, generated by Lpath's proprietary ImmuneY2(TM) platform ...Novel Drug Stops Cancer Growth
A first-of-its-kind drug effectively targets a molecule that fuels cancer cells and shows promise for stopping the ... Sphingomab is a monoclonal antibody. ...Lpath granted patent protection for anti-cancer anti-S1P antibody.
Lpath, Inc. (San Diego, CA) , the category leader in therapeuticagents against bioactive lipids, announced the issuance ... Sphingomab is potently anti ...